Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorization Paves The Way For Initiation Of GT-02287 Phase 2 Clinical Development In The U.S., Expected During Q3'26

뉴스 본문을 불러오고 있어요.

Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorization Paves The Way For Initiation Of GT-02287 Phase 2 Clinical Development In The U.S., Expected During Q3'26 | 웨이프 WAPE

Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorization Paves The Way For Initiation Of GT-02287 Phase 2 Clinical Development In The U.S., Expected During Q3'26

기사 요약

관련 종목

댓글 —